Trial to assess if Semaglutide with lifestyle intervention reduces sarcopenia risk in older adults.

Sarcopenia, the age-related loss of muscle mass, strength, and function, significantly impacts quality of life and increases morbidity in older adults. This condition is exacerbated in individuals with Type 2 diabetes (T2D) and obesity, where chronic inflammation and metabolic dysfunction accelerate muscle wasting. Current interventions often fall short in comprehensively addressing the complex interplay of these conditions. While Semaglutide effectively manages T2D and promotes weight loss, concerns exist regarding its potential to reduce lean muscle mass alongside fat mass. This trial aims to investigate if a structured multi-disciplinary lifestyle intervention can mitigate sarcopenia risk in this vulnerable population while on Semaglutide.

This is a clinical trial protocol recruiting older adults (aged 65-75) with Type 2 diabetes and obesity who are treated with Semaglutide. Participants will self-administer Semaglutide once weekly for 6 months. The intervention group will engage in an online exercise program and receive personal nutritional counseling, while the control group receives standard health recommendations. Clinic visits for checkups and tests will occur once every 8 weeks. Primary endpoints include changes in muscle mass, muscle strength, and physical function, with participants also maintaining diaries of exercise and food consumption.